Promestriene Affects GREB 1 Expression in Estrogen Sensitive Breast Cancer Cells

Promestriene (3-propyl ethyl, 17B-methyl estradiol) is a synthetic estrogen analogue with reported minimal systemic absorption which has been suggested for topical treatment of vaginal atrophy. Promestriene’s ability to stimulate proliferation and estrogen responsive gene expression was analyzed in estrogen receptor (ER+) positive breast cancer cell lines MCF-7, T-47D, and BT-474 using CFSE flow cytometric analysis, and quantitative RT-PCR analysis of GREB1 RNA expression, an estrogen responsive gene involved in estrogen receptor alpha expression. In estrogen replete conditions, Promestriene did not stimulate proliferation even at high concentrations (100,000 pg/ml). However, anti-estradiol depletion allowed low dose Promestriene (2 - 10 pg/ml) to stimulate GREB1 expression in all three cell lines at levels equal to that induced by estradiol (BT-474) or significantly higher than estradiol (MCF7 and T-47D). These findings suggest that Promestriene has the potential to support estrogen like cell signaling, a possible contraindication for use in treatment of vaginal atrophy associated with breast cancer aromatase inhibitor therapy.

• Publication year

  2015

• Venue

  Journal of Cancer Therapy

• Publication date

  2015-08-24

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4236/JCT.2015.69084
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State

  2015cited by this paper
• Oestrogen receptors in breast cancer: basic mechanisms and clinical implications

  2013cited by this paper
• Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor.

  2013cited by this paper
• Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor.

  2013cited by this paper
• Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator.

  2012cited by this paper
• Development of a highly sensitive method for the quantification of estrone and estradiol in serum by liquid chromatography tandem mass spectrometry without derivatization.

  2012cited by this paper
• Management of vaginal dryness and dyspareunia in estrogen sensitive cancer patients

  2012influential reference
• GREB1 Functions as a Growth Promoter and Is Modulated by IL6/STAT3 in Breast Cancer

  2012cited by this paper
• Inhibition of the proliferation of acquired aromatase inhibitor-resistant breast cancer cells by histone deacetylase inhibitor LBH589 (panobinostat)

  2012cited by this paper
• A modulated empirical Bayes model for identifying topological and temporal estrogen receptor α regulatory networks in breast cancer

  2011cited by this paper
• Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90

  2011cited by this paper
• A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

  2011cited by this paper
• Oestrogen receptor–co‐factor–chromatin specificity in the transcriptional regulation of breast cancer

  2011cited by this paper
• Persistent and non-persistent changes in gene expression result from long-term estrogen exposure of MCF-7 breast cancer cells.

  2011cited by this paper
• Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women.

  2010cited by this paper
• Urogenital disorders associated with oestrogen deficiency: the role of promestriene as topical oestrogen therapy

  2010cited by this paper
• Estrogen deprivation for breast cancer prevention.

  2007cited by this paper
• GREB1 is a critical regulator of hormone dependent breast cancer growth

  2005influential reference
• PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer.

  2000cited by this paper
• Absence of systemic hormonal effects in an oestradiol diether topically active on the vaginal mucosa.

  1982cited by this paper

• No citing papers are available for this paper.